$10.78 Billion Forecast for Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market by 2029, Backed by Demand and Innovation
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market From 2025 To 2029?
The market size for nucleic acid and gene therapies for neuromuscular disorders has seen robust growth in the past few years. This sector is expected to expand from $6.84 billion in 2024 to $7.5 billion in 2025, with a compound annual growth rate (CAGR) of 9.6%. The notable growth during the historical period can be credited to factors such as an uptick in regulatory approvals, escalating demand for nucleic acid-based treatments, the need for more accurate and effective therapies, increasing demand for successful gene therapies, and a rise in gene therapy-related discoveries.
A significant surge in the market size of nucleic acid and gene therapies in neuromuscular disorders is anticipated in the coming years. The market is projected to reach $10.78 billion by 2029, accelerating at a compound annual growth rate (CAGR) of 9.5%. Factors contributing to growth in the forecast period include a rise in genetic disorders, escalated R&D investments, increased demand for precision medicine, a boom in the approval of gene therapy products, and a rise in chronic disorders. The forecast period will also see trends like improvements in patient care, superior performance chromatography, inventive answers for conditions, progression in gene editing technologies, and the emergence of nucleic acid extraction technology.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp
What Are the Core Growth Drivers Propelling the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Forward?
The nucleic acid and gene therapies industry for neuromuscular ailments is expected to be spurred by the escalating incidence of genetic disorders. These diseases, originating from DNA abnormalities either inherited or from mutations, are on the rise due to factors such as genetic changes, environmental influences, lifestyle shifts, and enhanced diagnostic competencies. Nucleic acid and gene therapies intervene by rectifying or substituting defective genes in neuromuscular disorders to reinstate normal functioning. For example, as per Cure SMA, a US-based non-profit organization, roughly 9,000 to 9,500 individuals in America presently live with Spinal Muscular Atrophy (SMA) as of May 2024. Out of the total population, 37% are diagnosed with Type 2 SMA. The disease records an approximate incidence rate of 1 in 15,000 births. Consequently, the rising occurrence of genetic disorders is fueling the expansion of the nucleic acid and gene therapy sector for neuromuscular diseases.
What Segment Types Define the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Structure?
The nucleic acid and gene therapies in neuromuscular disordersmarket covered in this report is segmented –
1) By Disorder: Motor Neuron Diseases; Neuropathies; Neuromuscular Junction Disorders; Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy; Postnatal Gene Therapy; Spinal Muscular Atrophy
3) By Application: Hospitals; Specialty Clinics; Ambulatory Surgery Centers
Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS); Spinal Muscular Atrophy (SMA); Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT); Hereditary Sensory and Autonomic Neuropathy (HSAN); Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis; Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD); Becker Muscular Dystrophy (BMD); Limb-Girdle Muscular Dystrophy (LGMD); Facioscapulohumeral Muscular Dystrophy (FSHD)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21233&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2024. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing theNucleic Acid And Gene Therapies In Neuromuscular Disorders Industry Evolution?
The nucleic acid and gene therapies in neuromuscular disorders market is being actively engaged with by leading companies, who are putting their focus on developing groundbreaking therapies like gene therapy. This technique is designed to treat genetic neuromuscular disorders at their source through the modification or replacement of genes. It involves altering, adding, or fixing genetic material within the cells of a patient to replace or correct faulty genes. For instance, Sarepta Therapeutics Inc., a biotech firm based in the US, was approved by the U.S. Food and Drug Administration in June 2023 for Elevidys. This was the first-ever gene therapy specifically designed for ambulatory pediatric patients aged 4 to 5 years suffering from Duchenne Muscular Dystrophy. The treatment is administered through a single intravenous infusion, making it a simpler process than other treatments that may necessitate continual infusions. Elevidys provides a gene that encodes for a reduced form of dystrophin known as micro-dystrophin, crucial for muscle functionality. This novel method tackles the genetic defect at its root by allowing muscle cells to generate a working version of the dystrophin protein, which could potentially arrest or reverse the progression of the disease.
View the full report here:
What Is the Definition of the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
Nucleic acid and gene therapies in neuromuscular disorders refer to innovative treatments that aim to correct or compensate for the genetic mutations underlying these diseases. Neuromuscular disorders (NMDs) are conditions that affect the muscles and nerves, often due to inherited genetic mutations. These therapies involve the use of nucleic acids or genetic material to repair, replace, or modulate gene expression, thereby addressing the root cause of the disorder.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21233
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
